MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management 2018: A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment

MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management 2018: A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment is organized by David Geffen School of Medicine at University of California, Los Angeles (UCLA) and will be held on Feb 17, 2018 at UCLA Meyer and Renee Luskin Conference Center, Los Angeles, California, United States of America.

The target audience for this medical event is Radiologists, urologists, radiation and medical oncologists and primary care physicians interested in understanding prostate MR imaging and its applications for active surveillance, biopsy planning and acquisition, surgical planning and radiation planning and its role as a prostate biomarker. This CME Conference has been approved with a maximum of 8.00 AMA PRA Category 1 Credits.

Course Description :
Prostate cancer is the second most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high grade cancers who would benefit most from aggressive therapy and triage the rest to active surveillance. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup for prostate cancer, which has relied instead on transrectal US-guided template biopsy. Over the past few years, MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer and is considered a valuable biomarker. The course will focus on the evolving role of MR imaging in prostate cancer diagnosis, monitoring, targeted biopsy and in focal and whole gland therapy planning. We will review all relevant MR imaging components of prostate cancer, new molecular modalities such as PSMA PET and an update on prostate cancer biomarkers.

Conference Objectives are :
• Understand state-of-the art prostate MR imaging, biomarkers and artificial intelligence
• Integrate prostate MR imaging into active surveillance and targeted biopsy planning
• Incorporate prostate MR imaging into robotic prostatectomy and radiation planning
• Illustrate the role for molecular imaging of prostate cancer: PSMA, Axumin and Choline PET
• Evaluate the risks and benefits of focal and whole gland therapies